Ajinomoto Bio-Pharma Services Japan

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody DrugsView original content:https://www.prnewswire.co.uk/news-releases/successful-extension-of-nucleic-acid-aptamer-pharmacokinetics-in-joint-research-by-ajinomoto-co-inc-and-ribomic-inc-302447922.html